公开(公告)号：CA2981883A1

公开(公告)日：2016-10-20

申请号：CA2981883

申请日：2016-04-12

Applicant: ACADEMIA SINICA

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN ,  CHIU CHIUNG-YI ,  LIU I-JU ,  CHANG YU-LING

IPC: C07K16/28

Abstract: An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.

公开(公告)号：CA2809677A1

公开(公告)日：2012-03-08

申请号：CA2809677

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

IPC: C07K16/30 ,  A61K9/14 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K17/02 ,  C12N15/13 ,  G01N33/574

Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.

公开(公告)号：SG173593A1

公开(公告)日：2011-09-29

申请号：SG2011057023

申请日：2010-02-19

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  CHIU CHIEN-YU

Abstract: Cancer-targeting peptides and uses thereof in cancer therapy.

公开(公告)号：AU2015377230A1

公开(公告)日：2017-07-13

申请号：AU2015377230

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：CA2973886A1

公开(公告)日：2016-08-04

申请号：CA2973886

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/10 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30

Abstract: The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.

公开(公告)号：CA2972067A1

公开(公告)日：2016-07-21

申请号：CA2972067

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：AU2015206370A1

公开(公告)日：2016-07-07

申请号：AU2015206370

申请日：2015-01-16

Applicant: ACADEMIA SINICA

Inventor： LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  WONG CHI-HUEY

IPC: C12N5/0793

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：AU2011296085A1

公开(公告)日：2013-03-28

申请号：AU2011296085

申请日：2011-08-30

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： WU HAN-CHUNG ,  LU RUEI-MIN

IPC: C12P21/06

Abstract: Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.

公开(公告)号：CA2678013A1

公开(公告)日：2008-08-21

申请号：CA2678013

申请日：2008-02-12

Applicant: ACADEMIA SINICA ,  UNIV NAT TAIWAN

Inventor： LIN CHIN-TARNG ,  WU HAN-CHUNG ,  CHANG DE-KUAN

IPC: A61K9/127 ,  A61K47/48 ,  C07K7/04 ,  C12N15/09

Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung canc er and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens f rom lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeti ng phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorub icin, the efficacy of these drugs against human lung cancer xenografts was i mproved, the survival rate increased, and the drug toxicity was reduced.

公开(公告)号：CA2678051A1

公开(公告)日：2008-02-21

申请号：CA2678051

申请日：2008-02-12

Applicant: ACADEMIA SINICA ,  UNIV NAT TAIWAN

Inventor： WU HAN-CHUNG ,  LIN CHIN-TARNG ,  LEE TONG-YOUNG ,  KUO SZU-YAO

IPC: A61K9/127 ,  A61K47/48 ,  C07K7/04 ,  C12N15/09

Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovascul ature and were identified by in vivo phage display. One such peptide, SP5-52 , recognized the neovasculature of multiple tumors in SCED mice, but did not target normal blood vessels. This peptide also binds to blood vessels of hu man lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubici n enhanced the efficacy of the drug against multiple human cancer xenografts in SCED mice.